[go: up one dir, main page]

WO2003008583A3 - Nouvelles compositions et methodes relatives au cancer - Google Patents

Nouvelles compositions et methodes relatives au cancer Download PDF

Info

Publication number
WO2003008583A3
WO2003008583A3 PCT/US2001/051291 US0151291W WO03008583A3 WO 2003008583 A3 WO2003008583 A3 WO 2003008583A3 US 0151291 W US0151291 W US 0151291W WO 03008583 A3 WO03008583 A3 WO 03008583A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
novel compositions
cancer
present
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/051291
Other languages
English (en)
Other versions
WO2003008583A2 (fr
Inventor
David W Morris
Eric K Engelhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagres Discovery Inc
Original Assignee
Sagres Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/004,113 external-priority patent/US20030194702A1/en
Priority claimed from US10/052,482 external-priority patent/US20040072264A1/en
Priority claimed from US09/997,722 external-priority patent/US20040072154A1/en
Priority claimed from US10/034,650 external-priority patent/US20030216558A1/en
Application filed by Sagres Discovery Inc filed Critical Sagres Discovery Inc
Publication of WO2003008583A2 publication Critical patent/WO2003008583A2/fr
Publication of WO2003008583A3 publication Critical patent/WO2003008583A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur de nouvelles séquences utilisables à des fins de diagnostic et de traitement des carcinomes et en particulier des carcinomes de type lymphome. L'invention porte également sur l'utilisation de nouvelle compositions pour le dépistage.
PCT/US2001/051291 2001-03-02 2001-12-26 Nouvelles compositions et methodes relatives au cancer Ceased WO2003008583A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US79858601A 2001-03-02 2001-03-02
US09/798,586 2001-03-02
US10/004,113 2001-10-23
US10/004,113 US20030194702A1 (en) 2000-12-22 2001-10-23 Novel compositions and methods for cancer
US10/052,482 US20040072264A1 (en) 2000-12-22 2001-11-08 Novel compositions and methods for cancer
US10/052,482 2001-11-08
US09/997,722 2001-11-30
US09/997,722 US20040072154A1 (en) 2000-12-22 2001-11-30 Novel compositions and methods for cancer
US10/034,650 US20030216558A1 (en) 2000-12-22 2001-12-20 Novel compositions and methods for cancer
US10/034,650 2001-12-20

Publications (2)

Publication Number Publication Date
WO2003008583A2 WO2003008583A2 (fr) 2003-01-30
WO2003008583A3 true WO2003008583A3 (fr) 2003-07-03

Family

ID=27533041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051291 Ceased WO2003008583A2 (fr) 2001-03-02 2001-12-26 Nouvelles compositions et methodes relatives au cancer

Country Status (1)

Country Link
WO (1) WO2003008583A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists
US9353186B2 (en) 2011-06-03 2016-05-31 Bayer Intellectual Property Gmbh Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
CN108570510B (zh) * 2017-03-14 2021-07-09 河南科技大学 用于检测副猪嗜血杆菌的lamp引物、试剂盒及检测方法
CN109402117B (zh) * 2018-11-07 2022-03-01 上海中医药大学附属曙光医院 一种沉默小鼠肠道rasgrp1表达的腺相关病毒及其制备方法和应用

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JP3792655B2 (ja) 2003-01-20 2006-07-05 日本電気株式会社 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途
CA2515081A1 (fr) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
CA2516138A1 (fr) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
US20050283854A1 (en) 2003-05-23 2005-12-22 Anton Krumm Recombinant vectors for use in position-independent transgene expression within chromatin
EP1711606A2 (fr) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation de l'expression du r cepteur glucocortico de
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
GB0428301D0 (en) * 2004-12-24 2005-01-26 Immunoclin Ltd Resistance genes
US20090220495A1 (en) * 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
KR100790871B1 (ko) 2005-06-23 2008-01-03 삼성전자주식회사 심근 경색에 관련된 유전자 다형성 및 그의 용도
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
DE102006032424A1 (de) * 2006-07-13 2008-01-17 Ernst-Moritz-Arndt Universität Greifswald Behandlung von T-Zell-Malignomen
WO2009117018A1 (fr) * 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition de l'angiogenèse
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
AU2011213678B2 (en) 2010-02-04 2015-01-29 Eisai Inc. Chlorotoxin polypeptides and conjugates and uses thereof
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
WO2012136519A1 (fr) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Utilisation d'anticorps neutralisants dirigés contre les récepteurs à la prolactine en vue du traitement et de la prévention du cancer du sein résistant aux anti-œstrogènes
BR112014009790A2 (pt) 2011-10-25 2018-05-15 Isis Pharmaceuticals Inc composto para modulação antisense da expressão de gccr, seu uso e composição
US9688740B2 (en) * 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP2978440B1 (fr) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Traitement de la fibrose par inhibition de tl1a et diagnostic de fibrose par detection de li31ra
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3470081A1 (fr) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CA2973266A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de demyelinisation
WO2017075045A2 (fr) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Anticorps anti-b7-h1
CN118773299A (zh) 2016-03-17 2024-10-15 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
MX2020002124A (es) * 2017-08-25 2020-07-20 Zoetis Services Llc Un metodo para inmovilizar una sonda de acido nucleico a un soporte solido.
WO2019152657A1 (fr) 2018-02-03 2019-08-08 Simple Healthkit, Inc. Évaluation fiable, complète et rapide de la santé sexuelle
KR102653878B1 (ko) 2018-08-01 2024-04-01 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies)
WO2020092736A1 (fr) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Procédés et matériaux pour le traitement du cancer
EP3873500A4 (fr) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research Méthodes et matériaux de traitement du cancer
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HANSEN GWENN M ET AL: "Genetic profile of insertion mutations in mouse leukemias and lymphomas.", GENOME RESEARCH, vol. 10, no. 2, February 2000 (2000-02-01), pages 237 - 243, XP002223353, ISSN: 1088-9051 *
LEE SOO WOONG ET AL: "Cloning of mouse sepiapterin reductase gene and characterization of its promoter region.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1445, no. 1, 14 April 1999 (1999-04-14), pages 165 - 171, XP002223352, ISSN: 0006-3002 *
LI JIAYIN ET AL: "Leukaemia disease genes: Large-scale cloning and pathway predictions.", NATURE GENETICS, vol. 23, no. 3, November 1999 (1999-11-01), pages 348 - 353, XP002223354, ISSN: 1061-4036 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8932821B2 (en) 2003-03-19 2015-01-13 Biogen Idec Ma Inc. NOGO receptor binding protein
US9068992B2 (en) 2004-06-24 2015-06-30 Biogen Ma Inc. Screening methods for identifying Sp35 antagonists
US9353186B2 (en) 2011-06-03 2016-05-31 Bayer Intellectual Property Gmbh Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
CN108570510B (zh) * 2017-03-14 2021-07-09 河南科技大学 用于检测副猪嗜血杆菌的lamp引物、试剂盒及检测方法
CN109402117B (zh) * 2018-11-07 2022-03-01 上海中医药大学附属曙光医院 一种沉默小鼠肠道rasgrp1表达的腺相关病毒及其制备方法和应用

Also Published As

Publication number Publication date
WO2003008583A2 (fr) 2003-01-30

Similar Documents

Publication Publication Date Title
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2003045230A3 (fr) Compositions et procedes contre le cancer
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004063355A3 (fr) Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2003024392A3 (fr) Compositions et procedes pour le diagnostic et le traitement des tumeurs
WO2003000113A3 (fr) Compositions et procedes destines au diagnostic et au traitement de tumeurs
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
IL173352A0 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
EP1551388A4 (fr) Composes utiles dans le traitement du cancer, compositions et procedes correspondants
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2006110760A3 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2003039484A3 (fr) Nouvelles compositions et methodes pour le traitement du cancer
WO2004045545A3 (fr) Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer
WO2003071933A3 (fr) Nouvelles compositions et procedes de traitement du cancer
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP